Literature DB >> 25766244

cAMP-dependent activation of protein kinase A as a therapeutic target of skin hyperpigmentation by diphenylmethylene hydrazinecarbothioamide.

Hyoeun Shin1, Seung Deok Hong1, Eunmiri Roh1, Sang-Hun Jung2, Won-Jea Cho3, Sun Hong Park1, Da Young Yoon1, Seon Mi Ko1, Bang Yeon Hwang1, Jin Tae Hong1, Tae-Young Heo4, Sang-Bae Han1, Youngsoo Kim1.   

Abstract

BACKGROUND AND
PURPOSE: cAMP as a second messenger stimulates expression of microphthalmia-associated transcription factor (MITF) or the tyrosinase gene in UVB-induced skin pigmentation. Diphenylmethylene hydrazinecarbothioamide (QNT 3-80) inhibits α-melanocyte-stimulating hormone (α-MSH)-induced melanin production in B16 murine melanoma cells but its molecular basis remains to be defined. Here, we investigated the mechanism underlying the amelioration of skin hyperpigmentation by QNT 3-80. EXPERIMENTAL APPROACH: We used melanocyte cultures with raised levels of cAMP and UVB-irradiated dorsal skin of guinea pigs for pigmentation assays. Immunoprecipitation, kemptide phosphorylation, fluorescence analysis and docking simulation were applied to elucidate a molecular mechanism of QNT 3-80. KEY
RESULTS: QNT 3-80 inhibited melanin production in melanocyte cultures with elevated levels of cAMP, including those from human foreskin. This compound also ameliorated hyperpigmentation in vivo in UVB-irradiated dorsal skin of guinea pigs. As a mechanism, QNT 3-80 directly antagonized cAMP binding to the regulatory subunit of PKA, nullified the dissociation and activation of inactive PKA holoenzyme in melanocytes and fitted into the cAMP-binding site on the crystal structure of human PKA under the most energetically favourable simulation. QNT 3-80 consequently inhibited cAMP- or UVB-induced phosphorylation (activation) of cAMP-responsive element-binding protein in vitro and in vivo, thus down-regulating expression of genes for MITF or tyrosinase in the melanogenic process. CONCLUSIONS AND IMPLICATIONS: Our data suggested that QNT 3-80 could contribute significantly to the treatment of skin disorders with hyperpigmented patches with the cAMP-binding site of PKA as its molecular target.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25766244      PMCID: PMC4500377          DOI: 10.1111/bph.13134

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  Regulation of human skin pigmentation and responses to ultraviolet radiation.

Authors:  Yoshinori Miyamura; Sergio G Coelho; Rainer Wolber; Sharon A Miller; Kazumasa Wakamatsu; Barbara Z Zmudzka; Shosuke Ito; Christoph Smuda; Thierry Passeron; Wonseon Choi; Jan Batzer; Yuji Yamaguchi; Janusz Z Beer; Vincent J Hearing
Journal:  Pigment Cell Res       Date:  2007-02

Review 2.  Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase.

Authors:  Hideya Ando; Hirofumi Kondoh; Masamitsu Ichihashi; Vincent J Hearing
Journal:  J Invest Dermatol       Date:  2007-01-11       Impact factor: 8.551

Review 3.  The many faces of H89: a review.

Authors:  A Lochner; J A Moolman
Journal:  Cardiovasc Drug Rev       Date:  2006 Fall-Winter

Review 4.  Melanin pigmentary disorders: treatment update.

Authors:  Jean-Paul Ortonne; Thierry Passeron
Journal:  Dermatol Clin       Date:  2005-04       Impact factor: 3.478

Review 5.  Hypopigmenting agents: an updated review on biological, chemical and clinical aspects.

Authors:  Francisco Solano; Stefania Briganti; Mauro Picardo; Ghanem Ghanem
Journal:  Pigment Cell Res       Date:  2006-12

Review 6.  Regulating gene transcription in response to cyclic AMP elevation.

Authors:  William A Sands; Timothy M Palmer
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

7.  Downregulation of melanin synthesis by haginin A and its application to in vivo lightening model.

Authors:  Jin Hee Kim; Seung Hwa Baek; Dong Hyun Kim; Tae Young Choi; Tae Jin Yoon; Jae Sung Hwang; Mee Ree Kim; Ho Jeong Kwon; Choong Hwan Lee
Journal:  J Invest Dermatol       Date:  2007-11-22       Impact factor: 8.551

8.  PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation.

Authors:  Choel Kim; Cecilia Y Cheng; S Adrian Saldanha; Susan S Taylor
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

Review 9.  Regulation of melanogenesis--controversies and new concepts.

Authors:  Karin U Schallreuter; Sonal Kothari; Bhaven Chavan; Jennifer D Spencer
Journal:  Exp Dermatol       Date:  2007-12-31       Impact factor: 3.960

Review 10.  Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders.

Authors:  Genji Imokawa
Journal:  Pigment Cell Res       Date:  2004-04
View more
  5 in total

Review 1.  Hypopigmenting Effects of Brown Algae-Derived Phytochemicals: A Review on Molecular Mechanisms.

Authors:  Mohammed Shariful Azam; Jinkyung Choi; Min-Sup Lee; Hyeung-Rak Kim
Journal:  Mar Drugs       Date:  2017-09-24       Impact factor: 5.118

Review 2.  Potential Use of Seaweed Bioactive Compounds in Skincare-A Review.

Authors:  Valentina Jesumani; Hong Du; Muhammad Aslam; Pengbing Pei; Nan Huang
Journal:  Mar Drugs       Date:  2019-12-06       Impact factor: 5.118

3.  Molecular Mechanisms of Anti-Melanogenic Gedunin Derived from Neem Tree (Azadirachta indica) Using B16F10 Mouse Melanoma Cells and Early-Stage Zebrafish.

Authors:  Hwang-Ju Jeon; Kyeongnam Kim; Chaeeun Kim; Myoung-Jin Kim; Tae-Oh Kim; Sung-Eun Lee
Journal:  Plants (Basel)       Date:  2021-02-09

4.  A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent.

Authors:  Eun Ju Oh; Jong Il Park; Ji Eun Lee; Cheol Hwan Myung; Su Yeon Kim; Sung Eun Chang; Jae Sung Hwang
Journal:  Int J Mol Sci       Date:  2016-04-12       Impact factor: 5.923

5.  α-Viniferin Improves Facial Hyperpigmentation via Accelerating Feedback Termination of cAMP/PKA-Signaled Phosphorylation Circuit in Facultative Melanogenesis.

Authors:  Cheong-Yong Yun; Seon Mi Ko; Yong Pyo Choi; Beom Joon Kim; Jungno Lee; Jae Mun Kim; Ju Yeon Kim; Jin Yong Song; Song-Hee Kim; Bang Yeon Hwang; Jin Tae Hong; Sang-Bae Han; Youngsoo Kim
Journal:  Theranostics       Date:  2018-02-16       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.